Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients
September 07, 2016 03:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International Congress
August 24, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical Voted A “Best Places to Work” Company in the North San Francisco Bay Area
August 18, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 11th Annual North Bay...
Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results
August 04, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
Quarterly Revenue Increased 37.3% Year-Over-Year, to $32.0 Million Raptor Raises 2016 Global Net Revenue Guidance to $125-$135 Million Company to Host Conference Call and Webcast Today at...
Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT
July 28, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4,...
Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
May 05, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
PROCYSBI® Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million 2016 Non-GAAP Operating Expense Guidance Lowered to $125 – $135 Million Full-Year 2016 Revenue Guidance Maintained...
Raptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review
March 21, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI®...
Raptor Pharmaceutical to Participate in the Cowen and Company 36th Annual Health Care Conference
March 01, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...
Raptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy Activities
February 29, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its support of Rare Disease Week, beginning February 29, 2016, with a series of activities...
Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 05, 2015 16:04 ET
|
Raptor Pharmaceutical Inc
Record PROCYSBI® Product Sales of $25.8 Million
Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million
Company to Host Conference Call and Webcast Today at 4:30 p.m. EST
NOVATO,...